News

Posts are organized into categories for ease of navigation:

• Algorithm - developments to the interpretation algorithm implemented in Python.
• Announcement - general news related to the Molecular Oncology Almanac.
• Database - changes and additions to the underlying knowledge base.
• Release - aggregated release notes from GitHub releases (serving as the project changelog).

• Algorithm release 0.6.0 2024-05-31 Categories:  Algorithm, Release

  This release utilizes the v.2024-04-11 release of the underlying MOAlmanac database and primarily focuses on supporting Python 3.12. It incorporates changes from two pull requests: https://github.com/vanallenlab/moalmanac/pull/18 and https://github.com/vanallenlab/moalmanac/pull/19.

  Continue reading
• Database release 2024-04-11 Categories:  Database, Release

  Added entries:

  • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
  • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
  • (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
  • (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.
  Continue reading
• Database release 2024-03-07 Categories:  Database, Release

  Added entries:

  • (FDA) ALK fusions and sensitivity to crizotinib for patients with anaplastic large cell lymphoma.
  • (FDA) EGFR exon 20 insertions and sensitivity to amivantamab-vmjw in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer.
  • (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib in combination with cisplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer.
  • (FDA) EGFR exon 19 deletions or p.L858R and sensitivity to osimertinib for patients with metastatic non-small cell lung cancer.
  • (FDA) MET exon 14 splice site and deletion variants (exon 14 skipping) and sensitivity to tepotinib for patients with metastatic non-small cell lung cancer.
  Continue reading
• Database release 2024-02-01 Categories:  Database, Release

  Added entries:

  • (FDA) BRAF p.V600E/K and sensitivity to vemurafenib for patients with Erdheim-Chester disease.
  Continue reading
• Database release 2024-01-11 Categories:  Database, Release

  Added entries:

  • (FDA) ERBB2 amplification and sensitivity to neratinib in combination with capecitabine for patients with breast cancer.
  Continue reading